Additionally, due to data suggesting an increased thrombotic risk above 12.0 g/dL in ESA-treated chronic kidney disease-patients, we would advise against Hb-targets >12.0 g/dL in this patient group (Palmer, 2010). This evidence concerns the gene GSTM1 and chronic kidney disease.